Dr. Reddy's Laboratories Ltd ADR (RDY)

$11.90 +0.19 (1.62%)
Market Cap 9.93B
Revenue (ttm) 3.58B
Net Income (ttm) 456.00M
EPS (ttm) N/A
PE Ratio 24.91
Forward PE 26.17
Profit Margin 12.74%
Debt to Equity Ratio 0.19
Volume 3,143,700
Avg Vol 2,738,272
Day's Range N/A - N/A
Shares Out 834.67M
Stochastic %K 38%
Beta 0.28
Analysts Hold
Price Target $14.50

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeuti...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Address:
8-2-337, Road No. 3, Banjara Hills, Hyderabad, India
Jwa68
Jwa68 Sep. 13 at 5:55 PM
$GANX $COYA $RDY $XBI David Einhorn's two smallest market cap biotech companies in his portfolio by miles. He also sits on the board of The Michael J Fox Foundation. I have long said I fully expect both companies are acquired. I will make a friendly wager at least one of the two see a deal to be bought before early November, or just a month and a half from this very moment The one remaining will eventually follow. Also at a signicant multiple of its current valuation. This video is well done and will likely age very well.
1 · Reply
RealAvidTrader
RealAvidTrader Sep. 13 at 3:40 PM
$GANX $COYA $RDY Two Tiny Biotech Stocks Big Pharma Is About to Fight Over https://youtu.be/y9G56zEUl0U
0 · Reply
Jwa68
Jwa68 Sep. 8 at 12:07 PM
$COYA $RDY $BMY https://ir.coyatherapeutics.com/news/news-details/2026/Coya-Therapeutics-Announces-Publication-of-Preclinical-Study-Demonstrating-Combination-Immunomodulatory-Effects-of-COYA-303-in-a-Well-Established-Model-of-Peripheral-and-CNS-Inflammation/default.aspx
0 · Reply
Invescent
Invescent Jul. 24 at 1:35 PM
📊 Today's Trade Ideas 1️⃣ $RDY Momentum Setup • 68% Entry: $11.74 - $11.97 Target: $12.51 Stop: $11.33 Risk: Medium 2️⃣ $JGRO Momentum Setup • 54% Entry: $92.74 - $93.80 Target: $98.80 Stop: $89.48 Risk: High 3️⃣ $HALO Watchlist Setup • 44% Entry: $80.44 - $81.19 Target: $85.69 Stop: $77.61 Risk: Low Not financial advice.
0 · Reply
EarningsInsider
EarningsInsider Jul. 22 at 3:31 PM
https://www.marketbeat.com/earnings/reports/2026-7-22-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
0 · Reply
Robby83
Robby83 Jul. 21 at 7:40 PM
$COYA my only ticker not seeing big green... weird seeing SP so heavily tied to $RDY .
0 · Reply
InItToWinIt100
InItToWinIt100 Jun. 26 at 1:39 PM
$UNH Nice 5 pt pop! $RDY Up 1.5% so far
0 · Reply
InItToWinIt100
InItToWinIt100 Jun. 26 at 1:38 PM
Are you $RDY ?
0 · Reply
InItToWinIt100
InItToWinIt100 Jun. 26 at 2:21 AM
Watchlist for 6/26: $GRPN $AAPL $UNH $RDY $TII
1 · Reply
BillionerOfKing
BillionerOfKing Jun. 23 at 5:33 PM
$RDY Current Stock Price: $14.12 Contracts to trade: $15.0 RDY Jul 17 2026 Call Entry: $0.09 Exit: $0.13 ROI: 48% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on RDY
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

Tue, 08 Sep 2026 17:42:00 -0400 - 4 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

Thu, 03 Sep 2026 10:00:00 -0400 - 10 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

Tue, 01 Sep 2026 17:41:00 -0400 - 11 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

Thu, 27 Aug 2026 16:15:00 -0400 - 16 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

Tue, 25 Aug 2026 18:25:00 -0400 - 18 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

Dr Reddy’s arm Aurigene inks global drug manufacturing deal with pharma giant

2026-08-25T15:09:54.000Z - 19 days ago

Dr Reddy’s arm Aurigene inks global drug manufacturing deal with pharma giant

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Thu, 20 Aug 2026 11:00:00 -0400 - 24 days ago

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Thu, 20 Aug 2026 09:00:00 -0400 - 24 days ago

Dr. Reddy's Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Wed, 19 Aug 2026 18:17:00 -0400 - 24 days ago

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Dr. Reddy’s says FDA inspection of UK facility ‘officially closed’

2026-08-16T12:49:54.000Z - 4 weeks ago

Dr. Reddy’s says FDA inspection of UK facility ‘officially closed’

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Thu, 13 Aug 2026 20:00:00 -0400 - 4 weeks ago

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Wed, 05 Aug 2026 20:00:00 -0400 - 5 weeks ago

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s

2026-08-05T18:23:56.000Z - 5 weeks ago

Laurus Labs surges past Rs 1 lakh crore MCAP & biggies like Dr Reddy’s

Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S

2026-08-04T07:32:13.000Z - 5 weeks ago

Dr. Reddy's Launches First-to-Market Generic Sugammadex Injection In The U.S

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Tue, 04 Aug 2026 01:39:00 -0400 - 5 weeks ago

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr Reddy’s registers PD-1 inhibitor for rare head and neck cancer in South Africa

2026-08-03T16:12:11.000Z - 5 weeks ago

Dr Reddy’s registers PD-1 inhibitor for rare head and neck cancer in South Africa

Dr Reddy’s gets USFDA nod for Rituximab biosimilar

2026-08-01T14:05:18.000Z - 6 weeks ago

Dr Reddy’s gets USFDA nod for Rituximab biosimilar

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Fri, 31 Jul 2026 10:07:00 -0400 - 6 weeks ago

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

Wed, 29 Jul 2026 10:07:00 -0400 - 6 weeks ago

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

Tue, 28 Jul 2026 10:07:00 -0400 - 6 weeks ago

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

Thailand approves Nuzolvence antibiotic for gonorrhoea treatment

2026-07-27T16:33:10.000Z - 6 weeks ago

Thailand approves Nuzolvence antibiotic for gonorrhoea treatment

Trump's Tariffs Are Targeting Indian Drugmakers. Americans Could Soon Pay More for Generic Medicines, CEO Warns

2026-07-27T13:21:43.000Z - 6 weeks ago

Trump's Tariffs Are Targeting Indian Drugmakers. Americans Could Soon Pay More for Generic Medicines, CEO Warns

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

Fri, 24 Jul 2026 17:06:00 -0400 - 7 weeks ago

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

Fri, 24 Jul 2026 02:31:06 -0400 - 7 weeks ago

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

Thu, 23 Jul 2026 22:24:40 -0400 - 7 weeks ago

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors

2026-07-23T23:47:25.000Z - 7 weeks ago

Dr Reddy's Laboratories Ltd (RDY) Shares Surge 3.7% -- What GF Score of 83 Tells Investors

Dr Reddy's Laboratories Ltd Annual Shareholders Meeting Transcript

2026-07-23T12:00:18.000Z - 7 weeks ago

Dr Reddy's Laboratories Ltd Annual Shareholders Meeting Transcript

Dr. Reddy's Laboratories Q1 Net Profit Drops As Revenue Slips, Expenses Climb

2026-07-23T09:58:18.000Z - 7 weeks ago

Dr. Reddy's Laboratories Q1 Net Profit Drops As Revenue Slips, Expenses Climb

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

2026-07-23T07:29:50.000Z - 7 weeks ago

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes

Wed, 22 Jul 2026 23:55:45 -0400 - 7 weeks ago

Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes

A Look at Dr Reddy's Laboratories Ltd (RDY) After 9.4% Decline -- GF Value $14.70 vs Price $11.38

2026-07-22T22:44:07.000Z - 7 weeks ago

A Look at Dr Reddy's Laboratories Ltd (RDY) After 9.4% Decline -- GF Value $14.70 vs Price $11.38

Dr. Reddy's Laboratories Enters Oversold Territory (RDY)

2026-07-22T20:49:42.000Z - 7 weeks ago

Dr. Reddy's Laboratories Enters Oversold Territory (RDY)

Dr. Reddy's Laboratories Q1 Earnings Call Highlights

Wed, 22 Jul 2026 13:07:23 -0400 - 7 weeks ago

Dr. Reddy's Laboratories Q1 Earnings Call Highlights

Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

2026-07-22T15:56:39.000Z - 7 weeks ago

Trump's 200% tariff plan may be a bitter pill for US consumers, warns Dr Reddy's

Dr. Reddy's Laboratories Transcript: Q1 26/27

Jul 22, 2026, 10:00 AM EDT - 7 weeks ago

Dr. Reddy's Laboratories Transcript: Q1 26/27

Dr. Reddy's Laboratories Quarterly report: Q1 2027

Jul 22, 2026, 10:00 AM EDT - 7 weeks ago

Dr. Reddy's Laboratories Quarterly report: Q1 2027

Dr. Reddy's Laboratories Slides: Q1 2027

Jul 22, 2026, 10:00 AM EDT - 7 weeks ago

Dr. Reddy's Laboratories Slides: Q1 2027

Indian drugmaker Dr Reddy's posts quarterly profit slump

Wed, 22 Jul 2026 06:53:43 -0400 - 7 weeks ago

Indian drugmaker Dr Reddy's posts quarterly profit slump

Dr. Reddy's (RDY) Set to Release Q1 Earnings on July 22

2026-07-21T17:56:37.000Z - 7 weeks ago

Dr. Reddy's (RDY) Set to Release Q1 Earnings on July 22

Top stocks to buy today: Stock recommendations for July 15, 2026 - check list

2026-07-15T02:02:00.000Z - 2 months ago

Top stocks to buy today: Stock recommendations for July 15, 2026 - check list

Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk

Sun, 12 Jul 2026 17:02:55 -0400 - 2 months ago

Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk

India's Dr Reddy's extends slide as semaglutide setback threatens first-mover edge

2026-07-10T03:51:33.381Z - 2 months ago

India's Dr Reddy's extends slide as semaglutide setback threatens first-mover edge

Dr. Reddy's Laboratories (RDY) Faces Supply Delays Due to Quality Issues

2026-07-09T15:02:28.000Z - 2 months ago

Dr. Reddy's Laboratories (RDY) Faces Supply Delays Due to Quality Issues

India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice

Thu, 09 Jul 2026 08:23:12 -0400 - 2 months ago

India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice

Dr. Reddy's Laboratories Transcript: Investor update

Jul 9, 2026, 7:00 AM EDT - 2 months ago

Dr. Reddy's Laboratories Transcript: Investor update

Dr. Reddy’s Generic Ozempic Supplies Delayed on API Issue

2026-07-09T10:48:22.000Z - 2 months ago

Dr. Reddy’s Generic Ozempic Supplies Delayed on API Issue

Dr Reddy's delays semaglutide supply due to active ingredient issue

Thu, 09 Jul 2026 00:54:39 -0400 - 2 months ago

Dr Reddy's delays semaglutide supply due to active ingredient issue

A Look at Dr Reddy's Laboratories Ltd (RDY) After 3.5% Decline -- GF Value $15.27 vs Price $14.12

2026-07-09T00:32:05.000Z - 2 months ago

A Look at Dr Reddy's Laboratories Ltd (RDY) After 3.5% Decline -- GF Value $15.27 vs Price $14.12

Stocks to watch on brokerages today, June 1: Kotak Mahindra Bank, Hitachi Energy, Dr Reddy's Laboratories, MCX and more in focus

2026-07-01T02:48:31.000Z - 2 months ago

Stocks to watch on brokerages today, June 1: Kotak Mahindra Bank, Hitachi Energy, Dr Reddy's Laboratories, MCX and more in focus

Stocks to watch on brokerages today, July 1: Kotak Mahindra Bank, Hitachi Energy, Dr Reddy's Laboratories, MCX and more in focus

2026-07-01T02:48:31.000Z - 2 months ago

Stocks to watch on brokerages today, July 1: Kotak Mahindra Bank, Hitachi Energy, Dr Reddy's Laboratories, MCX and more in focus

Dr. Reddy's Laboratories announces ₹8 per share dividend for FY 2025-26

2026-06-30T14:26:10.000Z - 2 months ago

Dr. Reddy's Laboratories announces ₹8 per share dividend for FY 2025-26

Dr. Reddy's Laboratories releases integrated annual report for FY 2025-26

2026-06-30T14:12:22.000Z - 2 months ago

Dr. Reddy's Laboratories releases integrated annual report for FY 2025-26

Dr. Reddy's Laboratories reports 50% reduction in emissions for FY2025-26

2026-06-30T14:06:07.000Z - 2 months ago

Dr. Reddy's Laboratories reports 50% reduction in emissions for FY2025-26

Pharma sector stocks today, June 30: Ajanta Pharma falls 2.96%, Dr. Reddy's Lab down 1.77%, Aurobindo Pharma up 1.41%

2026-06-30T04:33:17.000Z - 2 months ago

Pharma sector stocks today, June 30: Ajanta Pharma falls 2.96%, Dr. Reddy's Lab down 1.77%, Aurobindo Pharma up 1.41%

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Jun 26, 2026, 11:10 AM EDT - 2 months ago

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

Innoviva announces distribution, licensing agreement with Dr. Reddy’s

2026-06-16T12:15:02.000Z - 2 months ago

Innoviva announces distribution, licensing agreement with Dr. Reddy’s

INVA

Dr. Reddy’s announces first-to-market launch of Bosutinib Tablets 400mg

2026-06-14T21:10:06.000Z - 3 months ago

Dr. Reddy’s announces first-to-market launch of Bosutinib Tablets 400mg

Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Jun 13, 2026, 6:22 AM EDT - 3 months ago

Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY

May 29, 2026, 8:55 AM EDT - 3 months ago

NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY

ASAN DELL IDT

Dr. Reddy’s launches generic Semaglutide injection in Canada

2026-05-17T15:45:31.000Z - 3 months ago

Dr. Reddy’s launches generic Semaglutide injection in Canada

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

May 16, 2026, 3:18 AM EDT - 4 months ago

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

Dr. Reddy's Laboratories Transcript: Q4 25/26

May 12, 2026, 10:00 AM EDT - 4 months ago

Dr. Reddy's Laboratories Transcript: Q4 25/26

Dr. Reddy's Laboratories Quarterly report: Q4 2026

May 12, 2026, 10:00 AM EDT - 4 months ago

Dr. Reddy's Laboratories Quarterly report: Q4 2026

Dr. Reddy's Laboratories Slides: Q4 2026

May 12, 2026, 10:00 AM EDT - 4 months ago

Dr. Reddy's Laboratories Slides: Q4 2026

Dr. Reddy's Laboratories Annual report: Q4 2026

May 12, 2026, 10:00 AM EDT - 4 months ago

Dr. Reddy's Laboratories Annual report: Q4 2026

Dr. Reddy's Laboratories Annual report: Q4 2026

May 12, 2026, 10:00 AM EDT - 4 months ago

Dr. Reddy's Laboratories Annual report: Q4 2026

Indian drugmaker Dr. Reddy's posts quarterly profit slump

May 12, 2026, 7:16 AM EDT - 4 months ago

Indian drugmaker Dr. Reddy's posts quarterly profit slump

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

Apr 29, 2026, 12:37 PM EDT - 4 months ago

Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic

Dr. Reddy’s announces Health Canada approval for Semaglutide Injection

2026-04-29T12:26:09.000Z - 4 months ago

Dr. Reddy’s announces Health Canada approval for Semaglutide Injection

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

Apr 29, 2026, 7:38 AM EDT - 4 months ago

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

Goldman downgrades Dr. Reddy’s to Sell on generic Ozempic concerns

2026-04-23T17:45:55.000Z - 4 months ago

Goldman downgrades Dr. Reddy’s to Sell on generic Ozempic concerns

Dr. Reddy’s downgraded to Sell from Neutral at Goldman Sachs

2026-04-23T17:41:31.000Z - 4 months ago

Dr. Reddy’s downgraded to Sell from Neutral at Goldman Sachs

Dr. Reddy’s awaiting approval for Semaglutide in Canada, CNBC-TV18 says

2026-04-23T16:07:08.000Z - 4 months ago

Dr. Reddy’s awaiting approval for Semaglutide in Canada, CNBC-TV18 says

LLY NVO

Dr. Reddy’s rally on CNBC report overstates upside, says Citi

2026-04-23T16:00:42.000Z - 4 months ago

Dr. Reddy’s rally on CNBC report overstates upside, says Citi

Dr. Reddy’s reports FDA acceptance to review Abatacept BLA

2026-02-20T16:00:22.000Z - 6 months ago

Dr. Reddy’s reports FDA acceptance to review Abatacept BLA

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Feb 20, 2026, 10:57 AM EST - 6 months ago

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

Dr. Reddy's Laboratories Transcript: Q3 25/26

Jan 21, 2026, 9:00 AM EST - 7 months ago

Dr. Reddy's Laboratories Transcript: Q3 25/26

Dr. Reddy's Laboratories Quarterly report: Q3 2026

Jan 21, 2026, 9:00 AM EST - 7 months ago

Dr. Reddy's Laboratories Quarterly report: Q3 2026

Dr. Reddy's Laboratories Slides: Q3 2026

Jan 21, 2026, 9:00 AM EST - 7 months ago

Dr. Reddy's Laboratories Slides: Q3 2026

Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

Jan 14, 2026, 8:49 AM EST - 8 months ago

Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

Immutep, Dr Reddy’s enters strategic collaboration for Eftilagimod Alfa

2025-12-08T13:21:25.000Z - 9 months ago

Immutep, Dr Reddy’s enters strategic collaboration for Eftilagimod Alfa

IMMP

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Dec 2, 2025, 8:00 AM EST - 9 months ago

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies

Dr. Reddy's Laboratories Transcript: Q2 25/26

Oct 24, 2025, 10:00 AM EDT - 10 months ago

Dr. Reddy's Laboratories Transcript: Q2 25/26

Dr. Reddy's Laboratories Quarterly report: Q2 2026

Oct 24, 2025, 10:00 AM EDT - 10 months ago

Dr. Reddy's Laboratories Quarterly report: Q2 2026

Dr. Reddy's Laboratories Slides: Q2 2026

Oct 24, 2025, 10:00 AM EDT - 10 months ago

Dr. Reddy's Laboratories Slides: Q2 2026

Esperion reaches settlement agreement with ANDA filer, Dr. Reddy’s

2025-10-03T12:06:29.000Z - 11 months ago

Esperion reaches settlement agreement with ANDA filer, Dr. Reddy’s

ESPR

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Aug 18, 2025, 8:16 AM EDT - 1 year ago

Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.

Dr. Reddy's Q1FY26 Financial Results

Jul 23, 2025, 1:46 PM EDT - 1 year ago

Dr. Reddy's Q1FY26 Financial Results

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Jul 23, 2025, 10:27 AM EDT - 1 year ago

India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says

Dr. Reddy's Laboratories Transcript: Q1 25/26

Jul 23, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Transcript: Q1 25/26

Dr. Reddy's Laboratories Quarterly report: Q1 2026

Jul 23, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Quarterly report: Q1 2026

Dr. Reddy's Laboratories Slides: Q1 2026

Jul 23, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Slides: Q1 2026

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)

Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

May 12, 2025, 3:51 AM EDT - 1 year ago

Generics won't be affected by Trump's pricing policy, says Dr. Reddy's

Dr. Reddy's Q4 & Full Year FY25 Financial Results

May 9, 2025, 2:53 PM EDT - 1 year ago

Dr. Reddy's Q4 & Full Year FY25 Financial Results

Dr. Reddy's Laboratories Transcript: Q4 24/25

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Transcript: Q4 24/25

Dr. Reddy's Laboratories Annual report: Q4 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Annual report: Q4 2025

Dr. Reddy's Laboratories Slides: Q4 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Slides: Q4 2025

Dr. Reddy's Laboratories Annual report: Q4 2025

May 9, 2025, 10:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Annual report: Q4 2025

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Mar 27, 2025, 11:47 AM EDT - 1 year ago

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Mar 18, 2025, 8:35 AM EDT - 1 year ago

Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Mar 13, 2025, 10:40 AM EDT - 1 year ago

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Feb 6, 2025, 7:51 AM EST - 1 year ago

Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Feb 6, 2025, 6:35 AM EST - 1 year ago

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Dr. Reddy's Q3 & 9MFY25 Financial Results

Jan 23, 2025, 12:35 PM EST - 1 year ago

Dr. Reddy's Q3 & 9MFY25 Financial Results

Dr. Reddy's Laboratories Transcript: Q3 24/25

Jan 23, 2025, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Transcript: Q3 24/25

Dr. Reddy's Laboratories Quarterly report: Q3 2025

Jan 23, 2025, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Quarterly report: Q3 2025

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Nov 28, 2024, 6:15 AM EST - 1 year ago

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Nov 26, 2024, 8:07 AM EST - 1 year ago

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Dr. Reddy's Q2 & H1FY25 Financial Results

Nov 5, 2024, 9:59 AM EST - 1 year ago

Dr. Reddy's Q2 & H1FY25 Financial Results

Dr. Reddy's Laboratories Transcript: Q2 24/25

Nov 5, 2024, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Transcript: Q2 24/25

Dr. Reddy's Laboratories Quarterly report: Q2 2025

Nov 5, 2024, 9:00 AM EST - 1 year ago

Dr. Reddy's Laboratories Quarterly report: Q2 2025

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Oct 25, 2024, 7:40 AM EDT - 1 year ago

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Oct 14, 2024, 9:47 AM EDT - 1 year ago

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Oct 8, 2024, 11:32 AM EDT - 1 year ago

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Oct 2, 2024, 11:10 AM EDT - 1 year ago

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Aug 20, 2024, 2:42 PM EDT - 2 years ago

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Dr. Reddy's Laboratories: India 'will be our number one market'

Jul 30, 2024, 8:25 PM EDT - 2 years ago

Dr. Reddy's Laboratories: India 'will be our number one market'

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Jul 29, 2024, 11:55 AM EDT - 2 years ago

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Q1FY25 Financial Results

Jul 27, 2024, 9:51 AM EDT - 2 years ago

Dr. Reddy's Q1FY25 Financial Results

Dr. Reddy's Laboratories Transcript: Q1 24/25

Jul 27, 2024, 7:00 AM EDT - 2 years ago

Dr. Reddy's Laboratories Transcript: Q1 24/25

Dr. Reddy's Laboratories Quarterly report: Q1 2025

Jul 27, 2024, 7:00 AM EDT - 2 years ago

Dr. Reddy's Laboratories Quarterly report: Q1 2025

Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Jun 26, 2024, 11:26 AM EDT - 2 years ago

Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Dr. Reddy's Laboratories Transcript: M&A Announcement

Jun 26, 2024, 9:30 AM EDT - 2 years ago

Dr. Reddy's Laboratories Transcript: M&A Announcement

Dr. Reddy's Laboratories Press release: M&A Announcement

Jun 26, 2024, 9:30 AM EDT - 2 years ago

Dr. Reddy's Laboratories Press release: M&A Announcement

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

Jun 3, 2024, 1:05 PM EDT - 2 years ago

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

Dr. Reddy's Laboratories Slides: Investor presentation

Jun 1, 2024, 6:30 AM EDT - 2 years ago

Dr. Reddy's Laboratories Slides: Investor presentation

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

May 28, 2024, 9:53 AM EDT - 2 years ago

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

Jwa68
Jwa68 Sep. 13 at 5:55 PM
$GANX $COYA $RDY $XBI David Einhorn's two smallest market cap biotech companies in his portfolio by miles. He also sits on the board of The Michael J Fox Foundation. I have long said I fully expect both companies are acquired. I will make a friendly wager at least one of the two see a deal to be bought before early November, or just a month and a half from this very moment The one remaining will eventually follow. Also at a signicant multiple of its current valuation. This video is well done and will likely age very well.
1 · Reply
RealAvidTrader
RealAvidTrader Sep. 13 at 3:40 PM
$GANX $COYA $RDY Two Tiny Biotech Stocks Big Pharma Is About to Fight Over https://youtu.be/y9G56zEUl0U
0 · Reply
Jwa68
Jwa68 Sep. 8 at 12:07 PM
$COYA $RDY $BMY https://ir.coyatherapeutics.com/news/news-details/2026/Coya-Therapeutics-Announces-Publication-of-Preclinical-Study-Demonstrating-Combination-Immunomodulatory-Effects-of-COYA-303-in-a-Well-Established-Model-of-Peripheral-and-CNS-Inflammation/default.aspx
0 · Reply
Invescent
Invescent Jul. 24 at 1:35 PM
📊 Today's Trade Ideas 1️⃣ $RDY Momentum Setup • 68% Entry: $11.74 - $11.97 Target: $12.51 Stop: $11.33 Risk: Medium 2️⃣ $JGRO Momentum Setup • 54% Entry: $92.74 - $93.80 Target: $98.80 Stop: $89.48 Risk: High 3️⃣ $HALO Watchlist Setup • 44% Entry: $80.44 - $81.19 Target: $85.69 Stop: $77.61 Risk: Low Not financial advice.
0 · Reply
EarningsInsider
EarningsInsider Jul. 22 at 3:31 PM
https://www.marketbeat.com/earnings/reports/2026-7-22-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
0 · Reply
Robby83
Robby83 Jul. 21 at 7:40 PM
$COYA my only ticker not seeing big green... weird seeing SP so heavily tied to $RDY .
0 · Reply
InItToWinIt100
InItToWinIt100 Jun. 26 at 1:39 PM
$UNH Nice 5 pt pop! $RDY Up 1.5% so far
0 · Reply
InItToWinIt100
InItToWinIt100 Jun. 26 at 1:38 PM
Are you $RDY ?
0 · Reply
InItToWinIt100
InItToWinIt100 Jun. 26 at 2:21 AM
Watchlist for 6/26: $GRPN $AAPL $UNH $RDY $TII
1 · Reply
BillionerOfKing
BillionerOfKing Jun. 23 at 5:33 PM
$RDY Current Stock Price: $14.12 Contracts to trade: $15.0 RDY Jul 17 2026 Call Entry: $0.09 Exit: $0.13 ROI: 48% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
briefingcom
briefingcom May. 18 at 12:36 PM
$RDY: Dr. Reddy's launches its generic semaglutide injection in Canada https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260518061903RDY&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
AlertsAndNews
AlertsAndNews May. 16 at 7:46 PM
$RDY $NVO Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada "The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada"
1 · Reply
MarketBeat
MarketBeat May. 14 at 12:11 PM
https://marketbeat.com/a/8654460/ $RDY Dr. Reddy's Laboratories Q4 Earnings Call Highlights
0 · Reply
EarningsInsider
EarningsInsider May. 12 at 9:21 PM
https://www.marketbeat.com/earnings/reports/2026-5-12-dr-reddys-laboratories-limited-stock/ $RDY Dr. Reddy's Laboratories Earnings Transcr
0 · Reply
ontariomark
ontariomark May. 12 at 6:53 PM
$RDY News: Dr. Reddy’s to sell Ozempic generics in Canada in days (RDY)
0 · Reply
SuperGreenToday
SuperGreenToday May. 12 at 2:20 PM
$RDY Share Price: $12.34 Contract Selected: Dec 18, 2026 $12.5 Calls Buy Zone: $2.68 – $3.31 Target Zone: $4.58 – $5.60 Potential Upside: 62% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
CapitalMonk
CapitalMonk May. 12 at 10:54 AM
$RDY Price: $13.14 (-0.68%) Trend: Bearish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.88% RSI: 56.8 | Momentum: Moderate Volume: +21.1% vs avg Volatility: 1.96% Support: $12.77 | Resistance: $14.20 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
MStocktwit
MStocktwit Apr. 30 at 5:20 PM
$NVO $RDY $LLY Exact copy from the Novo with different branded label. Better than a Generic. Approved last year. Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply
Gnomsayin
Gnomsayin Apr. 29 at 7:48 PM
$LLY $NVO $RDY
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 6:02 PM
$NVO $RDY $LLY Novo changes the label and you have the generic ready to go. Source http://www.endorhealth.com/article/generic-ozempic-coming-to-canada#:~:text=Eli%20Lilly%20has%20stated%20it,rebranded%20versions%20on%20December%2022%3A
0 · Reply
MStocktwit
MStocktwit Apr. 29 at 5:48 PM
$NVO $RDY $LLY In December 2025, Health Canada approved two Novo Nordisk rebranded versions on December 22: Plosbrio (identical to Ozempic) Poviztra (identical to Wegovy)
0 · Reply